Medical Bulletin 09/June/2026 - Video

Here are the top medical news for today:

Scientists Identify Blood Marker That Detects Lung Cancer Years Earlier

The earliest warning sign of lung cancer may not come from a scan—it could already be circulating in the bloodstream years before the disease appears.

A new study published in Cell has identified a unique blood-based protein signature that can predict a person's risk of developing lung cancer more than five years before diagnosis. The discovery could help doctors identify high-risk individuals much earlier, creating opportunities for prevention before cancer develops.

Researchers analyzed more than 48,000 blood samples and uncovered a pattern involving 14 proteins that consistently predicted future lung cancer risk. The findings were validated across eight independent international datasets and were observed not only in smokers but also in people who had never smoked.

Scientists believe the protein signature does not originate from an existing tumor. Instead, it appears to reflect chronic inflammation and biological changes occurring in the lungs long before cancer becomes detectable. This suggests that lung cancer may be preceded by a previously unrecognized "pre-disease" phase, during which intervention could potentially reduce risk.

Lung cancer remains the leading cause of cancer-related deaths worldwide. One major challenge is that many cases are diagnosed only after symptoms develop, when treatment options are often less effective. Current screening programs primarily focus on older adults with a significant smoking history, leaving many at-risk individuals outside eligibility criteria.

The newly identified blood signature could eventually help expand screening beyond traditional high-risk groups. Researchers say it may also help identify people who could benefit from preventive therapies aimed at stopping cancer before it starts.

The findings add to growing evidence that chronic inflammation may play a key role in the early stages of several age-related diseases. According to the research team, the same biological processes detected in the study may also help explain why certain lung diseases develop years before symptoms appear.

While more studies are needed before the test can be used in clinical practice, the discovery moves scientists closer to a future where lung cancer risk can be detected years in advance.

REFERENCE: Pandya T, Zagorulya M, Leung M, et al.; Plasma signals of lung tumor promotion for molecular cancer prevention; Cell, 2026; DOI: 10.1016/j.cell.2026.05.005

AI-Developed Coronavirus Vaccine Shows Promise in First Human Trial

A vaccine designed to fight future coronavirus threats before they emerge has successfully passed its first human clinical trial.

Researchers from the University of Cambridge and biotechnology company DIOSynVax have developed an experimental "universal" coronavirus vaccine that aims to protect against an entire family of related viruses rather than a single strain. The early-stage study found the vaccine was safe and well tolerated in 39 healthy volunteers, with no significant side effects reported.

Unlike conventional vaccines that target viruses already circulating in humans, the new approach focuses on shared features found across the Sarbecovirus family, which includes the virus behind COVID-19, the SARS virus, and several related coronaviruses currently circulating in bats.

The vaccine uses an artificial intelligence-designed "super-antigen"—a single engineered protein created by analyzing genetic information from multiple coronaviruses. Instead of training the immune system against one virus, the super-antigen teaches it to recognize characteristics common to many related viruses, including strains that may emerge in the future.

Researchers say this could help break the cycle of constantly updating vaccines to keep pace with new variants. Current vaccines often need reformulation as viruses evolve, but a universal vaccine could potentially provide broader and longer-lasting protection.

The trial showed that participants developed immune responses not only against known human coronaviruses but also against related bat viruses that have not yet crossed into humans. This suggests the vaccine may offer protection against future spillover events that could trigger new outbreaks.

Another unique aspect of the study was the delivery method. Instead of a traditional needle injection, the vaccine was administered using a needle-free microfluidic jet system that delivers the vaccine through the skin using high-pressure fluid. Researchers believe this approach could improve vaccine acceptance and simplify mass vaccination campaigns.

Scientists caution that the vaccine remains in the early stages of development. Larger Phase 2 trials are planned to evaluate its effectiveness in a broader population and confirm whether it can generate strong, wide-ranging protection.

If future studies are successful, the technology could represent a major shift in pandemic preparedness, allowing scientists to develop vaccines that anticipate viral evolution rather than react to it after outbreaks begin.

REFERENCE: Alasdair PS Munro, Matteo Ferrari, Rebecca Kinsley, Daniel Egan, Sneha Vishwanath, Thomas Bower, Andrew Chan, Matthew Davies, Joanne Marie M. Del Rosario, Ron Moss, Yvanne Enever, Benedict Asbach, Ralf Wagner, Rachel Bousfield, Krishna Chatterjee, Victoria Cornelius, Saul N. Faust, Jonathan L. Heeney. A phase I, needle free, dose escalation clinical trial of pEVAC-PS, a candidate pan-Sarbecovirus Vaccine. Journal of Infection, 2026; 92 (6): 106759 DOI: 10.1016/j.jinf.2026.106759

Major Collagen Review Separates Proven Benefits From Popular Health Claims

Collagen supplements finally put to the test—and the results separate science from hype.

From promises of wrinkle-free skin to claims of faster workout recovery, collagen has become one of the wellness industry's biggest trends. But the most comprehensive review of collagen research to date suggests that while some benefits are real, others may be overstated.

Published in the Aesthetic Surgery Journal Open Forum, the analysis pooled data from 16 systematic reviews, 113 randomized controlled trials, and nearly 8,000 participants worldwide. Researchers found that collagen supplementation can improve skin health and help ease symptoms of osteoarthritis, but offers little evidence of enhancing athletic performance.

One of the strongest findings involved skin health. People who took collagen consistently experienced improvements in skin hydration and elasticity, with longer periods of supplementation generally producing better results. Researchers say these effects may support healthier skin aging over time.

Collagen also showed benefits for people with osteoarthritis. Longer-term use was linked to reductions in joint pain and stiffness, suggesting it may help improve comfort and mobility in individuals affected by the condition.

Beyond skin and joints, the review found modest evidence that collagen may support muscle mass, muscle structure, and tendon health. However, the improvements were generally moderate rather than dramatic.

In contrast, the study found little support for popular claims that collagen boosts sports performance. Researchers reported no meaningful improvements in exercise recovery, muscle soreness, or overall athletic performance, challenging a major marketing message often aimed at fitness enthusiasts.

Researchers concluded that collagen is not a miracle supplement, but it may offer genuine benefits for skin health and osteoarthritis when used consistently. They also emphasized the need for more high-quality studies to determine optimal doses, long-term effects, and whether different collagen sources produce different results.

REFERENCE: Roshan Ravindran, Damiano Pizzol, José Francisco López-Gil, Masoud Rahmati, Laurent Boyer, Guillaume Fond, Laurie Butler, Angelica Stellato, Julia Gawronska, Yvonne Barnett, Helen Keyes, Pinar Soysal, Rafet Eren, Burak Onal, Dong Keon Yon, Lee Smith. Collagen Supplementation for Skin and Musculoskeletal Health: An Umbrella Review of Meta-Analyses on Elasticity, Hydration, and Structural Outcomes. Aesthetic Surgery Journal Open Forum, 2026; 8 DOI: 10.1093/asjof/ojag018